Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2424–2427. doi: 10.1128/aac.41.11.2424

Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.

B Allaouchiche 1, D Breilh 1, H Jaumain 1, B Gaillard 1, S Renard 1, M C Saux 1
PMCID: PMC164139  PMID: 9371344

Abstract

The objective of this study was to analyze the pharmacokinetics of cefepime, in six patients with acute renal failure related to septic shock, during continuous venovenous hemodiafiltration (CVVHD) (Hemospal AN 69S hemofilter; Hospal, Lyon, France). Six patients, mean age 65 +/- 4 years (range, 61 to 69), were included and each received 2 g of cefepime by intravenous infusion over a 30-min period every 12 h. Prefilter serum, dialysate outlet (DO), and ultrafiltrate samples were collected 0.47, 0.50, 0.57, 1, 3, 5, 7, and 12 h after the beginning of infusion. The time design of samples was optimized in accordance with the theory of D optimality. The cefepime concentrations were measured by high-performance liquid chromatography. The pharmacokinetics computation was carried out using P-PHARM software. Mean serum concentration peaks were 53 +/- 21.9 mg/liter (range, 13.0 to 68.9) one-half hour after the infusion. The mean elimination half-life was 8.11 +/- 2.22 h (range, 4.76 to 10.84). DO clearance was 66.57 +/- 30.14 ml/min (range, 38.66 to 119.87). The mean volume of distribution was 0.71 +/- 0.37 liters/kg of body weight. CVVHD was effective for cefepime elimination. In these subjects, the elimination half-life and DO clearance were almost constant. The results of this study suggested that a 2-g twice-daily infusion (usual dosage) was required for an effective concentration in this group of patients.

Full Text

The Full Text of this article is available as a PDF (216.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbhaiya R. H., Forgue S. T., Gleason C. R., Knupp C. A., Pittman K. A., Weidler D. J., Martin R. R. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother. 1990 Jun;34(6):1118–1122. doi: 10.1128/aac.34.6.1118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbhaiya R. H., Forgue S. T., Gleason C. R., Knupp C. A., Pittman K. A., Weidler D. J., Movahhed H., Tenney J., Martin R. R. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992 Mar;36(3):552–557. doi: 10.1128/aac.36.3.552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barbhaiya R. H., Knupp C. A., Forgue S. T., Matzke G. R., Guay D. R., Pittman K. A. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther. 1990 Sep;48(3):268–276. doi: 10.1038/clpt.1990.149. [DOI] [PubMed] [Google Scholar]
  4. Bellomo R., Teede H., Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensive Care Med. 1993;19(6):329–332. doi: 10.1007/BF01694706. [DOI] [PubMed] [Google Scholar]
  5. Bressolle F., Kinowski J. M., de la Coussaye J. E., Wynn N., Eledjam J. J., Galtier M. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994 Jun;26(6):457–471. doi: 10.2165/00003088-199426060-00004. [DOI] [PubMed] [Google Scholar]
  6. Cotterill S. Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother. 1995 Nov;36(5):773–780. doi: 10.1093/jac/36.5.773. [DOI] [PubMed] [Google Scholar]
  7. Cunha B. A., Gill M. V. Cefepime. Med Clin North Am. 1995 Jul;79(4):721–732. doi: 10.1016/s0025-7125(16)30035-9. [DOI] [PubMed] [Google Scholar]
  8. D'Argenio D. Z. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm. 1981 Dec;9(6):739–756. doi: 10.1007/BF01070904. [DOI] [PubMed] [Google Scholar]
  9. Davies J. G., Kingswood J. C., Sharpstone P., Street M. K. Drug removal in continuous haemofiltration and haemodialysis. 1995 Nov 15-Dec 12Br J Hosp Med. 54(10):524–528. [PubMed] [Google Scholar]
  10. Geronemus R. P., Schneider N. S., Epstein M. Survival in patients treated with continuous arteriovenous hemodialysis for acute renal failure and chronic renal failure. Preliminary observations. Contrib Nephrol. 1991;93:29–31. doi: 10.1159/000420180. [DOI] [PubMed] [Google Scholar]
  11. Hancock R. E., Bellido F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother. 1992 Apr;29 (Suppl A):1–6. doi: 10.1093/jac/29.suppl_a.1. [DOI] [PubMed] [Google Scholar]
  12. Hardin T. C., Jennings T. S. Cefepime. Pharmacotherapy. 1994 Nov-Dec;14(6):657–668. [PubMed] [Google Scholar]
  13. Keller F., Wilms H., Schultze G., Offerman G., Molzahn M. Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol. 1983 Apr;19(4):201–205. [PubMed] [Google Scholar]
  14. Kieft H., Hoepelman A. I., Knupp C. A., van Dijk A., Branger J. M., Struyvenberg A., Verhoef J. Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother. 1993 Nov;32 (Suppl B):117–122. doi: 10.1093/jac/32.suppl_b.117. [DOI] [PubMed] [Google Scholar]
  15. Nikaido H., Liu W., Rosenberg E. Y. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother. 1990 Feb;34(2):337–342. doi: 10.1128/aac.34.2.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Reetze-Bonorden P., Böhler J., Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet. 1993 May;24(5):362–379. doi: 10.2165/00003088-199324050-00002. [DOI] [PubMed] [Google Scholar]
  17. Schetz M., Ferdinande P., Van den Berghe G., Verwaest C., Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 1995 Jul;21(7):612–620. doi: 10.1007/BF01700172. [DOI] [PubMed] [Google Scholar]
  18. Tam P. Y., Huraib S., Mahan B., LeBlanc D., Lunski C. A., Holtzer C., Doyle C. E., Vas S. I., Uldall P. R. Slow continuous hemodialysis for the management of complicated acute renal failure in an intensive care unit. Clin Nephrol. 1988 Aug;30(2):79–85. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES